A future for regulatory science in the European Union: the European Medicines Agency’s strategy

被引：0
|
作者：
Philip A. Hines
Rosanne Janssens
Rosa Gonzalez-Quevedo
Apolline I.O.M. Lambert
Anthony J. Humphreys
机构：
来源：
Nature Reviews Drug Discovery | 2020年 / 19卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
After 3 years of co-design with stakeholders and EU regulatory partners, the European Medicines Agency’s Regulatory Science to 2025 strategy has been finalized. Here, we highlight the core recommendations that stakeholders deem most significant to advance evidence generation.
引用
收藏
页码：293 / 294
页数：1
相关论文
共 50 条
  • [1] A future for regulatory science in the European Union: the European Medicines Agency's strategy
    Hines, Philip A.
    Janssens, Rosanne
    Gonzalez-Quevedo, Rosa
    Lambert, Apolline I. O. M.
    Humphreys, Anthony J.
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2020, 19 (05) : 293 - 294
  • [2] Regulatory Science to 2025: An Analysis of Stakeholder Responses to the European Medicines Agency's Strategy
    Hines, Philip A.
    Gonzalez-Quevedo, Rosa
    Lambert, Apolline I. O. M.
    Janssens, Rosanne
    Freischem, Barbara
    Edo, Jordi Torren
    Claassen, Ivo J. T. M.
    Humphreys, Anthony J.
    [J]. FRONTIERS IN MEDICINE, 2020, 7
  • [3] The European Medicines Agency's goals for regulatory science to 2025
    Hines, Philip A.
    Guy, Richard H.
    Humphreys, Anthony J.
    Papaluca-Amati, Marisa
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2019, 18 (06) : 403 - 404
  • [4] The European Medicines Agency’s goals for regulatory science to 2025
    Philip A. Hines
    Richard H. Guy
    Anthony J. Humphreys
    Marisa Papaluca-Amati
    [J]. Nature Reviews Drug Discovery, 2019, 18 : 403 - 404
  • [5] Future of the European Union regulatory network in the context of the uptake of new medicines
    Hoebert, Jolle M.
    Irs, Alar
    Mantel-Teeuwisse, Aukje K.
    Leufkens, Hubert G. M.
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 76 (01) : 1 - 6
  • [6] The European medicines evaluation agency, its impact on clinical trials in the European Union
    Sauer, F
    [J]. EUROPEAN MEDICINES RESEARCH: PERSPECTIVES IN CLINICAL TRIALS, 1996, : 49 - 52
  • [7] Drug Policy for an Aging Population - The European Medicines Agency's Geriatric Medicines Strategy
    Cerreta, Francesca
    Eichler, Hans-Georg
    Rasi, Guido
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (21): : 1972 - 1974
  • [8] THE EUROPEAN MEDICINES AGENCY: A PUBLIC HEALTH EUROPEAN AGENCY?
    Mahalatchimy, Aurelie
    Rial-Sebbag, Emmanuelle
    De Grove-Valdeyron, Nathalie
    Tournay, Virginie
    Cambon-Thomsen, Anne
    Duguet, Anne-Marie
    Taboulet, Florence
    [J]. MEDICINE AND LAW, 2012, 31 (01): : 25 - 42
  • [9] European Medicines Agency
    Camarero, J.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S38 - S39
  • [10] Effect of European Medicines Agency's regulatory measures on nimesulide utilization in Portugal
    Pinto, Daniel
    Silva, Ana
    Heleno, Bruno
    Rodrigues, David Silverio
    Santos, Isabel
    Caetano, Pedro A.
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2018, 27 (06) : 630 - 637
12345